Midazolam intranasal spray - MEDIR

Drug Profile

Midazolam intranasal spray - MEDIR

Alternative Names: Nasal spray midazolam - MEDIR

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MEDIR
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Epilepsy; Sedation

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Sep 2015 Midazolam intranasal spray is available for commercialisation (MEDIR website, September 2015)
  • 03 Sep 2015 MEDIR has patent protection for midazolam nasal spray in USA, Europe, China and Russia (Commonwealth of Independent States) before September 2015 (MEDIR website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top